French MPs OK bill raising industry levy and imposing price cuts
This article was originally published in Scrip
Executive Summary
The lower house of the French parliament has passed the 2012 social security financing bill (PLFSS), which among other things will increase the sales-based contribution on the pharmaceutical industry, boost the use of generics and impose drug price cuts, as part of a drive to keep healthcare spending within set limits.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.